Loading...
These authors sought to provide further evidence for a role of anandamide and other endocannabinoids in neuroinflammatory disease. They measured anandamide, 2-arachidonoylglycerol, and the related compounds palmitoylethanolamide (PEA) and oleoylethanolamide in CSF samples from 20 healthy control subjects and 50 patients with multiple sclerosis (MS) in various stages of disease progression.
Concentrations of all four substances were significantly lower in patients with MS than in controls. The largest reduction was in anandamide, particularly in patients with secondary progressive disease (their mean value was less than half that of controls). In addition, levels of anandamide and PEA were higher in patients with MS in relapse, compared with …